

CLAIMS

- Sub  
A12
- 5 1. A composition comprising an amphoteric surfactant, an alkoxyated cetyl alcohol and a polar drug.
2. A composition according to claim 1 wherein the drug is an anionic drug.
- Sub  
A13
- 10 3. A composition according to claim 1 or claim 2 wherein the amphoteric surfactant is a balanced amphoteric surfactant.
4. A composition according to any of the preceding claims wherein the alkoxyated cetyl alcohol is Procetyl AWS.
- 15 5. A composition according to any of the preceding claims wherein the amphoteric surfactant comprises disodium coacoamphodiacetate.
6. A composition according to any of the preceding claims wherein the
- 20 drug comprises sodium cromoglycate or nedocromil sodium.
7. A composition according to any one of claims 1 to 5 wherein the drug comprises a corticosteroid or an antibacterial agent.
- 25 8. A composition according to any one of claims 1 to 5 wherein the drug comprises an antirheumatic agent, nicotine or a hormone.
- Sub  
A14
9. A composition according to claim 6 wherein the composition further comprises a corticosteroid.

Sub  
A14  
cont.

10. A composition according to any one of the preceding claims wherein the composition comprises an aqueous phase and an oil phase.

Sub  
C3

11. A composition according to claim 10 wherein the composition is an oil-in-water emulsion.

Sub  
A15

12. A composition according to any one of the preceding claims wherein the composition is a foam.

10

13. A composition according to any of the preceding claims consisting substantially of:

sorbitan tristearate or non-ionic emulsifying wax 0.5 to 5% w/v

glycerol monostearate 0.5 to 5% w/v

15

light liquid paraffin 1 to 20% w/v

white soft paraffin 1 to 10% w/v

iso propyl myristate 0.5 to 5% w/v

drug 0.1 to 20% w/v

disodium edetate 0.01 to 1% w/v

20

amphoteric surfactant 0.1 to 10% w/v

alkoxylated cetyl alcohol 0.1 to 10% w/v

triclosan 0.01 to 1% w/v

benzyl alcohol 0.01 to 1% w/v

purified water to 100% v/v of the emulsion

25

14. A stable oil-in-water emulsion comprising sodium cromoglycate, wherein when the emulsion is applied to skin an amount of sodium cromoglycate penetrates the skin that is sufficient to produce a demonstrable effect in the treatment of atopic dermatitis/eczema.

Sub  
A16  
5 15. A method of treatment of a skin disease or condition wherein a drug is applied to the skin of an individual affected by the disease or condition in or with a formulation comprising alkoxyated cetyl alcohol and an amphoteric surfactant.

16. Use of an alkoxyated cetyl alcohol and an amphoteric surfactant in the manufacture of a medicament for the treatment of a skin disease or condition.

10  
Sub  
A17  
15 17. A method of treatment of a skin disease or condition comprising applying a composition or emulsion according to any one of claims 1 to 14 to the skin of an individual affected by the disease or condition.

15 18. Use of a composition or emulsion according to any one of claims 1 to 14 in a method of treating a skin disease or condition.

20 19. Use of a composition or emulsion according to any one of claims 1 to 14 in the manufacture of a medicament for the treatment of a skin disease or condition.

Sub  
A18  
25 20. Use according to claim 18 or 19 wherein the disease or condition is one in which skin mast cells and/or delayed (cellular) hypersensitivity reactions and/or inflammation is thought to be involved.

21. Use according to any one of claims 18 to 20 in which the disease or condition is atopic dermatitis or eczema, contact sensitivity, psoriasis, drug sensitivity reactions, aphthous ulcers, Behçet's syndrome, pemphigus, urticaria, urticaria pigmentosa, pyoderma gangrenosum, chronic skin

ulcers, ulcers associated with Crohn's disease, burns, insect stings/bites, herpetic infections, systemic sclerosis (systemic scleroderma), morphea (circumscribed or localised scleroderma), dermal nodular fibrosis or sunburn.

5

22. The use according to claim 16, 18 to 21 or method according to claim 15 or 17 wherein the skin disease or condition is, has been or will be further treated by application of a corticosteroid.

10

23. A method of treatment of a patient in need of a polar drug comprising applying a composition or emulsion according to any one of claims 1 to 13 comprising the said polar drug to the skin of the said patient.

15

24. The use of a composition or emulsion according to any one of claims 1 to 13 in a method of treating a patient in need of the said polar drug.

20

25. The method of claim 23 or use of claim 24 wherein the said patient is a patient with arthritis and wherein the said polar drug is a polar anti-inflammatory or antirheumatic agent.

25

26. The method of claim 23 or use of claim 24 wherein the said patient is a patient with acne and wherein the said polar drug is a polar antibacterial drug.

27. The method of claim 23 or use of claim 24 wherein the said patient is a patient in need of nicotine and wherein the said polar drug is nicotine.

28. The composition or emulsion of any one of claims 1 to 14 packaged in a tube, tub, bottle or pressurised aerosol container.

Sub  
A18  
cont.

05704143-020104

Sub  
A19

24-11-99

29. A composition or emulsion according to any one of claims 1 to 14 for use in medicine.

5 30. A composition, method or use according to any of claims 1 to 13 or 15 to 29 (when dependent on claims 1 to 13), wherein the alkoxyated cetyl alcohol is polypropoxylated cetyl alcohol.

add B<sup>7</sup>

[illegible]

AMENDED SHEET